A potent statin with a hidden risk

Cerivastatin was the most potent statin ever marketed on a milligram-for-milligram basis. Approved in the late 1990s, it achieved clinically meaningful LDL reduction at doses as low as 0.3mg — a fraction of the doses required by other statins. Bayer marketed it as Baycol in the US and Lipobay in Europe.

By the time of its withdrawal, approximately 6 million patients had been prescribed the drug worldwide. The lipid-lowering efficacy was not in question. The problem was rhabdomyolysis — the catastrophic breakdown of skeletal muscle that, in severe cases, leads to myoglobinuria, acute renal failure, and death.

The interaction that trials missed

All statins carry some risk of myopathy and rhabdomyolysis, related to their inhibition of HMG-CoA reductase in skeletal muscle. But cerivastatin's rhabdomyolysis rate was dramatically higher than its class comparators — 10 to 50 times higher at equivalent lipid-lowering doses.

The critical factor was a drug-drug interaction with gemfibrozil, a fibrate commonly co-prescribed with statins for patients with mixed dyslipidemia. Gemfibrozil inhibits the glucuronidation pathway that is cerivastatin's primary route of metabolism. Co-administration resulted in cerivastatin plasma levels increasing several-fold, pushing muscle exposure into a toxic range.

This interaction was pharmacokinetically predictable from the known metabolic pathways. But it had never been studied in a dedicated drug-drug interaction trial during development. The pre-approval clinical program tested cerivastatin in relatively healthy patients with straightforward hypercholesterolemia — not the complex polypharmacy environment of real-world practice.

The withdrawal

By mid-2001, the FDA had received reports of 31 US deaths from cerivastatin-associated rhabdomyolysis, with 12 additional deaths reported internationally. The majority involved concomitant gemfibrozil use. Bayer voluntarily withdrew cerivastatin from the global market in August 2001.

The withdrawal had lasting consequences for drug development. Regulatory agencies significantly strengthened requirements for drug-drug interaction studies as part of pre-approval programs. The FDA's subsequent guidance on in vitro and clinical drug interaction studies reflected lessons learned directly from the cerivastatin experience.